ArticleRadiology and oncology2020
Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer.
Article in Radiology and oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 6 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- CT-derived myosteatosis as a predictor of postoperative outcomes in esophagogastric cancer surgery: a systematic review.Frontiers in medicine · 2026Pooled it
- Pooled it
- The impact of sarcopenia on esophagectomy for cancer: a systematic review and meta-analysis.BMC surgery · 2023Pooled it
- Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.Nutrients · 2023Pooled it
- The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review.Journal of cachexia, sarcopenia and muscle · 2021Pooled it
- Article
- Article
- The prognostic value of CT-measured body composition combined with radiomics in predicting the survival of patients with resectable colon cancer.La Radiologia medica · 2026Article
- Impact of Preoperative Comprehensive Body Composition on Postoperative Outcomes in Patients with Esophageal Cancer.Journal of clinical medicine · 2025Article
- Predictive value of myosteatosis and subcutaneous adipose tissue on the prognosis of ESCC patients undergoing chemoradiotherapy.Scientific reports · 2025Article
- Body composition alterations in patients with lung cancer.American journal of physiology. Cell physiology · 2025Review
- Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia.Skeletal radiology · 2025Article
- Fully-automated CT derived body composition analysis reveals sarcopenia in functioning adrenocortical carcinomas.Scientific reports · 2024Article
- Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.Annals of surgical oncology · 2024Article
- Association Between Body Composition and Survival in Patients With Gastroesophageal Adenocarcinoma: An Automated Deep Learning Approach.JCO clinical cancer informatics · 2024Article
- Influence of skeletal muscle and intermuscular fat on postoperative complications and long-term survival in rectal cancer patients.Journal of cachexia, sarcopenia and muscle · 2024Article
- Program with last minute abstracts of the Padua Days on Muscle and Mobility Medicine, 27 February - 2 March, 2024 (2024Pdm3).European journal of translational myology · 2024Article
- Article
- Influence of nutritional status and body composition on postoperative events and outcome in patients treated for primary localized retroperitoneal sarcoma.Radiology and oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Esophageal cancer remains a disease with poor survival and many complications. Measuring muscle mass and quality can identify patients with diminished muscle mass (sarcopenia) and muscle fat infiltration (myosteatosis). We studied the impact of sarcopenia and myosteatosis in resectable esophageal cancer on overall survival and complications. Patients and methods 139 patients received a radical esophagectomy. Skeletal muscle area (SMA) and muscle attenuation (MA) in CT images at L3 level were recorded and groups with and without sarcopenia and myosteatosis were compared for overall survival (OS), perioperative mortality, conduit complications, pleuropulmonary complications, respiratory failure requiring mechanical ventilation and other significant complications. Results Prevalence of sarcopenia and myosteatosis at presentation was 16.5% and 51.8%, respectively. Both were associated with decreased OS. Median survival was 18.3 months (CI 5.4-31.1) vs 31.0 months (CI 7.4-54.6) for sarcopenia/no sarcopenia (log rank p = 0.042) and 19.0 months (CI 13.3-24.7) vs 57.1 months (CI 15.2-99.0) for myosteatosis (log rank p = 0.044), respectively. A relationship between sarcopenia and myosteatosis and other negative outcomes after esophagectomy could not be established. Conclusions Sarcopenia and myosteatosis before esophagectomy are associated with decreased overall survival but not with more frequent perioperative complications. Identification of patients at risk can guide therapeutic decisions and interventions aimed at replenishing muscle reserves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.